Share Name Share Symbol Market Type Share ISIN Share Description
Epistem LSE:EHP London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 85.00p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.7 -3.4 -30.2 - 15.89

Epistem Share Discussion Threads

Showing 226 to 248 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
02/8/2016
13:54
Trading update. Monitoring the progress closely.
the ghost who walks
29/7/2016
08:30
https://genedrive.com/assays/documentation.phpJust found on the new website. Monitoring this one closely.
the ghost who walks
29/7/2016
08:21
Wondering if the new website will have upgraded investor relations disclosures. Closely watching.
the ghost who walks
29/7/2016
07:05
We need a progress update. Look at the Cepheid Genexperts site - so much information and news flow about their own Tb/RIF assay. Their system is larger and more expensive than GDRs, but they appear to already occupy the same market in India market that GDR are trying to get into. I expected the new CEO to have made more positive noises by now. To make my position clear, I am not invested now, having lost money during Mathew Walls disastrous era, however I still like the overall concept and package hence would pile in again if the problems I believe have existed are now resolved.
azzi
29/7/2016
06:16
New website also? Monitoring.
the ghost who walks
27/7/2016
13:44
Mgt bought shares. Monitoring closely
the ghost who walks
27/7/2016
13:43
Looking forward to the next update. Name change interesting
the ghost who walks
26/7/2016
06:50
A progress update would be nice on the take up go the Tb assay in zinnia. Also, more details on the HCV assay, when is this planned to be launched and where?
azzi
25/7/2016
09:25
Name change... Watching with interest
the ghost who walks
07/7/2016
20:59
They must be getting closer to releasing a progress update on the uptake of the Tb test in India. Very little news flow since the new CEO took over, who knows where this company will go. Sorry, my post is of no real help at all, just releasing some frustration.
azzi
05/5/2016
19:06
Very interesting. Watching closely.
the ghost who walks
04/5/2016
18:39
Ok - some positive news flow at last. As I understand, every assay developed needs successful chemistry, of course, however I have been more worried about the gene drive device itself, I think this is where the problems are or have been. Let's hope it's the latter. Watching closely.
azzi
04/5/2016
18:39
Ok - some positive news flow at last. As I understand, every assay developed needs successful chemistry, of course, however I have been more worried about the gene drive device itself, I think this is where the problems are or have been. Let's hope it's the latter. Watching closely.
azzi
04/5/2016
18:39
Ok - some positive news flow at last. As I understand, every assay developed needs successful chemistry, of course, however I have been more worried about the gene drive device itself, I think this is where the problems are or have been. Let's hope it's the latter. Watching closely.
azzi
04/5/2016
07:26
Video interview with David Budd http://tinyurl.com/ho7fhrz David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says recent tests show its rapid diagnostic system Genedrive is “as accurate as the gold standard”. Genedrive, which has already launched in India for TB, performed well in EU-funded hepatitis (HCV) study carried out by Institut Pasteur and Hopital Cochin in Paris. It was 100% accurate in detecting inherited genetic polymorphisms in Hepatitis (HCV) patients compared to the current 'gold-standard' laboratory test, Roche's TaqMan PCR. “We feel that based on the results that we’ve had today with Institut Pasteur on the qualitative side of detecting HCV that we are in a great position now to go out and find partners that will work with us on commercialising and taking that product to market,” Budd says.
proactivest
18/4/2016
14:53
Video interview with David Budd http://tinyurl.com/z9crjeq David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says the news it has reached a major milestone in its development with the full commercial launch of its Genedrive tuberculosis (TB) and antibiotic resistance test, is “hugely significant”. The company, a specialist in molecular diagnostics and personalised medicine, has teamed up with Xcelris Labs to start selling the product in India. Next up, Budd says, the company hopes to build up a “menu of tests” over time, now that the company has a “robust technology platform in place”.
proactivest
18/4/2016
07:00
This is good
the ghost who walks
31/3/2016
07:57
More smoke and mirror`s!! So the Indian Tb launch has been delayed! ..."and the delay in developing sales of Genedrive(R) and associated TB tests in India". They are only now embarking on "launch training" with their distribution partner - what the hell of they been doing for the last three years? I remain concerned that there are still problems with the Genedrive technology, they are claiming validation in some testing centers, however this is a bare minimum requirement for any technology and does not prove they are ready to scale up to meet the market needs. The Indian Tb market will be hard to break into, meaningful sales may be years away. I can`t get a feel for their strategy for their hepatitis C assay, this seems to still be at the development phase. Ads for "IL28" - I can`t find out what on earth this is for! Can someone enlighten me? Share placing coming up and clear concerns about future funding have once again put me off investing. I will continue to watch this disaster unfold. Very sad! Azzi
azzi
21/3/2016
08:36
I`m watching for evidence that it might be worth me re-investing again. However with the lack of information against the backdrop of a falling sp, I remain worried that more delays are taking place. The big question to me is what is the cause of the delays. I have been expecting a positive update on the Indian Tb strategy, but I can`t find anything at all. I wonder what the new CEO is uncovering?
azzi
20/3/2016
20:31
What's your expectation Azzi?
the ghost who walks
09/3/2016
15:19
I wonder what delays they are going to announce next......?
azzi
19/2/2016
15:04
Actually earlier than anticipated. Great
the ghost who walks
19/2/2016
08:54
Ceo start date confirmed.
the ghost who walks
Chat Pages: 10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20161206 14:14:19